XML 26 R9.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Cash, Cash Equivalents and Marketable Securities | 9 Months Ended
--- | ---
Sep. 30, 2017
Cash Cash Equivalents And Short Term Investments [Abstract] |
Cash, Cash Equivalents and Marketable Securities | 3. Cash, cash equivalents and marketable securities Cash, cash equivalents and marketable securities consist of the following (in thousands):
| Amortized Cost |  |  | Unrealized Gains |  |  | Unrealized Losses |  |  | Estimated Fair Value |
September 30, 2017 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash | $ | 2,972 |  |  | $ | - |  |  | $ | - |  |  | $ | 2,972 |
Money market funds |  | 14,124 |  |  |  | - |  |  |  | - |  |  |  | 14,124 |
Corporate debt securities |  | 3,000 |  |  |  | - |  |  |  | - |  |  |  | 3,000 |
Total cash and cash equivalents |  | 20,096 |  |  |  | - |  |  |  | - |  |  |  | 20,096 |
Marketable securities available-for-sale: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasuries |  | 33,664 |  |  |  | - |  |  |  | (15 | ) |  |  | 33,649 |
U.S. government agency securities |  | 95,748 |  |  |  | - |  |  |  | (17 | ) |  |  | 95,731 |
Corporate debt securities |  | 42,200 |  |  |  | 4 |  |  |  | - |  |  |  | 42,204 |
Total marketable securities available-for-sale |  | 171,612 |  |  |  | 4 |  |  |  | (32 | ) |  |  | 171,584 |
Total cash, cash equivalents and marketable securities | $ | 191,708 |  |  | $ | 4 |  |  | $ | (32 | ) |  | $ | 191,680 |
December 31, 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash | $ | 3,557 |  |  | $ | - |  |  | $ | - |  |  | $ | 3,557 |
Money market funds |  | 18,981 |  |  |  | - |  |  |  | - |  |  |  | 18,981 |
U.S. government agency securities |  | 1,751 |  |  |  | - |  |  |  | - |  |  |  | 1,751 |
Total cash and cash equivalents |  | 24,289 |  |  |  | - |  |  |  | - |  |  |  | 24,289 |
Marketable securities available-for-sale: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasuries |  | 3,499 |  |  |  | - |  |  |  | - |  |  |  | 3,499 |
U.S. government agency securities |  | 28,685 |  |  |  | 3 |  |  |  | (2 | ) |  |  | 28,686 |
Corporate debt securities |  | 24,938 |  |  |  | 5 |  |  |  | (2 | ) |  |  | 24,941 |
Total marketable securities available-for-sale |  | 57,122 |  |  |  | 8 |  |  |  | (4 | ) |  |  | 57,126 |
Total cash, cash equivalents and marketable securities | $ | 81,411 |  |  | $ | 8 |  |  | $ | (4 | ) |  | $ | 81,415 |
The maturities of our marketable securities available-for-sale are as follows (in thousands):
|  | September 30, 2017 |
|  | Amortized Cost |  |  | Estimated Fair Value |
Mature in one year or less |  | $ | 171,612 |  |  | $ | 171,584 |
Mature after one year through two years |  |  | - |  |  |  | - |
|  | $ | 171,612 |  |  | $ | 171,584 |
There were no realized gains or losses from the sale of marketable securities during the nine months ended September 30, 2017 and 2016. We have classified our entire investment portfolio as available-for-sale and available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities, with unrealized gains and losses included in accumulated other comprehensive loss in stockholders’ equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are included in interest income or expense. The cost of securities sold is based on the specific identification method. Management assesses whether declines in the fair value of investment securities are other than temporary. In determining whether a decline is other than temporary, management considers the following factors:
| • | Whether the investment has been in a continuous realized loss position for over 12 months;
| • | the duration to maturity of our investments;
| • | our intention and ability to hold the investment to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost bases;
| • | the credit rating, financial condition and near-term prospects of the issuer; and
| • | the type of investments made.
To date, there have been no declines in fair value that have been identified as other than temporary.

X
- Definition The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -URI http://asc.fasb.org/topic&trid=2122426 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -URI http://asc.fasb.org/topic&trid=2196928 + Details
Name: | us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration